Page last updated: 2024-12-11

rwj 54428

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

RWJ 54428: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9873517
CHEMBL ID285117
MeSH IDM0379595

Synonyms (14)

Synonym
rwj-54428
CHEMBL285117
mc 02479
mc-02479
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-5-chloro-4-thiazolyl)(hydroxyimino)acetyl)amino)-3-((3-(((2-aminoethyl)thio)methyl)-4-pyridinyl)thio)-8-oxo-, (6r-(6alpha,7beta(z)))-
unii-jt9jmj39uf
jt9jmj39uf ,
rwj 54428
189448-35-9
(6r,7r)-7-[[(2z)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-[3-(2-aminoethylsulfanylmethyl)pyridin-4-yl]sulfanyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-(((2z)-2-(2-amino-5-chloro-thiazol-4-yl)-2-hydroxyimino-acetyl)amino)-3-((3-(2-aminoethylsulfanylmethyl)-4-pyridyl)sulfanyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
rwj54428
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-5-chloro-4-thiazolyl)(hydroxyimino)acetyl)amino)-3-((3-(((2-aminoethyl)thio)methyl)-4-pyridinyl)thio)-8-oxo-, (6r-(6.alpha.,7.beta.(z)))-
mc-02,479

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The percentage of a 24-h dosing interval that the unbound serum RWJ-54428 concentrations exceeded the MIC (fT>MIC) was the pharmacokinetic (PK)-PD parameter that best described the efficacy of RWJ-54428."( Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection model.
Corcoran, E; Dudley, MN; Griffith, DC; Rodriguez, D, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" The percentage of a 24-h dosing interval that the unbound serum RWJ-54428 concentrations exceeded the MIC (fT>MIC) was the pharmacokinetic (PK)-PD parameter that best described the efficacy of RWJ-54428."( Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection model.
Corcoran, E; Dudley, MN; Griffith, DC; Rodriguez, D, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID438297Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID205668In vitro inhibition of growth of methicillin-resistant Staphylococcus aureus MRSA ATCC 335893 (clinical isolates)2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
New anti-MRSA cephalosporins with a basic aminopyridine at the C-7 position.
AID438298Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID205669In vitro inhibition of growth of methicillin-resistant Staphylococcus aureus MRSA spain 356 (clinical isolates)2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
New anti-MRSA cephalosporins with a basic aminopyridine at the C-7 position.
AID205667In vitro inhibition of growth of methicillin-resistant Staphylococcus aureus MRSA 76 (clinical isolates)2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
New anti-MRSA cephalosporins with a basic aminopyridine at the C-7 position.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]